Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 402Triple Negative Breast Neoplasms 64Neoplasm Metastasis 50Neoplasms 19Breast Neoplasms, Male 14Colorectal Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 11Pancreatic Neoplasms 11Colonic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Inflammatory Breast Neoplasms 6HER2-positive Breast Cancer 6Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Breast Cancer 5Rectal Neoplasms 4HER2 Positive Metastatic Breast Cancer 4Breast Cancer Metastatic 4Sarcoma 3Prostatic Neoplasms 3Meningeal Neoplasms 3Lymphoma, Non-Hodgkin 3Gallbladder Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Unknown Primary 2

Interventions

palbociclib 2Trastuzumab 2Capecitabine 2trastuzumab deruxtecan 1tetrathiomolybdate 1sacituzumab govitecan 1pembrolizumab 1niraparib 1inavolisib 1giredestrant 1eribulin 1avelumab 1atezolizumab 1abemaciclib 1Zymosan 1Radiotherapy 1Letrozole 1Immunotherapy 1Hydroxychloroquine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm, Residual × Capecitabine × Breast × Clear all
NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Stanford University

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡